CollPlant Biotechnologies (CLGN) Consolidated Net Income (2017 - 2026)

CollPlant Biotechnologies (CLGN) has 10 years of Consolidated Net Income data on file, last reported at -$3.1 million in Q1 2026.

• Quarterly Consolidated Net Income fell 89.02% year-over-year to -$3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$35.4 million (down 421.98% YoY) and the FY2025 annual result came in at -$39.9 million, down 1.67% from the prior year.
• Consolidated Net Income climbed to -$3.1 million in Q1 2026, from -$32.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $5.5 million in Q2 2023 to a low of -$32.0 million in Q4 2025.
• A 5-year average of -$4.2 million and a median of -$3.5 million in 2025 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2023 — Consolidated Net Income surged 231.52% — and 2025, when it sank 578.47%.
• Tracing CLGN's Consolidated Net Income over 5 years: stood at -$27.1 million in 2022, then soared by 81.49% to -$5.0 million in 2023, then grew by 6.15% to -$4.7 million in 2024, then slumped by 578.47% to -$32.0 million in 2025, then surged by 90.26% to -$3.1 million in 2026.
• The last three Consolidated Net Income figures came in at -$3.1 million (Q1 2026), -$32.0 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.